Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: The impact of competing causes of mortality and patient stratification

European Urology

Volumn 64, Issue 4, 2013, Pages 557-564

  Abdollah, Firas ^a   Boorjian, Stephen ^b   Cozzarini, Cesare ^a   Suardi, Nazareno ^a   Sun, Maxine ^c   Fiorino, Claudio ^a   Di Muzio, Nadia ^a   Karakiewicz, Pierre I ^c   Montorsi, Francesco ^a   Karnes, R Jeffrey ^b   Briganti, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MAYO CLINIC   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adjuvant; Neoplasm recurrence; Prostatic neoplasms mortality; Prostatic neoplasms pathology; Prostatic neoplasms surgery; Radiotherapy; Risk factors

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LONG TERM SURVIVAL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NOMOGRAM; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

ADJUVANT; NEOPLASM RECURRENCE; PROSTATIC NEOPLASMS/MORTALITY; PROSTATIC NEOPLASMS/PATHOLOGY; PROSTATIC NEOPLASMS/SURGERY; RADIOTHERAPY; RISK FACTORS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DECISION SUPPORT TECHNIQUES; HUMANS; KALLIKREINS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NOMOGRAMS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883772686     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.006     Document Type: Article

References (29)

1. M.R. Cooperberg, J.W. Moul, and P.R. Carroll The changing face of prostate cancer J Clin Oncol 23 2005 8146 8151
2. F. Abdollah, M. Sun, and A. Briganti Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy BJU Int 108 2011 1769 1775
3. F. Abdollah, M. Sun, and R. Thuret Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer Eur Urol 58 2010 882 892
4. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
5. M. Bolla, H. van Poppel, and B. Tombal Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
6. I.M. Thompson Jr., C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2006 2329 2335
7. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
8. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
9. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
10. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
11. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality J Clin Oncol 25 2007 1765 1771
12. T.K. Choueiri, M.H. Chen, and A.V. D'Amico Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death Cancer 116 2010 1887 1892
13. A.E. Teeter, J.C. Presti Jr., and W.J. Aronson Does PSADT after radical prostatectomy correlate with overall survival?-a report from the SEARCH database group Urology 77 2011 149 153
14. E.S. Antonarakis, Z. Feng, and B.J. Trock The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up BJU Int 109 2012 32 39
15. E.S. Antonarakis, Y. Chen, and S.I. Elsamanoudi Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database BJU Int 108 2011 378 385
16. M.K. Buyyounouski, T. Pickles, L.L. Kestin, R. Allison, and S.G. Williams Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer J Clin Oncol 30 2012 1857 1863
17. J.F. Ward, M.L. Blute, J. Slezak, E.J. Bergstralh, and H. Zincke The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 2003 1872 1876
18. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
19. S.A. Boorjian, M.K. Tollefson, R.H. Thompson, L.J. Rangel, E.J. Bergstralh, and R.J. Karnes Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy J Urol 188 2012 1761 1766
20. F.J. Bianco Jr., P.T. Scardino, and J.A. Eastham Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta") Urology 66 Suppl 2005 83 94
21. C. Cozzarini, F. Montorsi, and C. Fiorino Need for high radiation dose (>or=70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients Int J Radiat Oncol Biol Phys 75 2009 966 974
22. F.E. Harrell Jr., R.M. Califf, and D.B. Pryor Evaluating the yield of medical tests JAMA 247 1982 2543 2546
23. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
24. M.W. Kattan, J.A. Eastham, and A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
25. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
26. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Amer Statist Assoc 94 1999 496 509
27. F. Abdollah, M. Sun, and R. Thuret A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006 Eur Urol 59 2011 88 95
28. M. Pfirrmann, G. Ehninger, and C. Thiede Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial LancetOncol 13 2012 207 214
29. A. Briganti, J.R. Karnes, and L.F. Da Pozzo Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261 270